HHS Awards $752K for In-Vitro Diagnostic Substances to Roche Diagnostics, Serving Indian Health Service
Contract Overview
Contract Amount: $75,230 ($75.2K)
Contractor: Roche Diagnostics Corporation
Awarding Agency: Department of Health and Human Services
Start Date: 2024-12-10
End Date: 2025-03-31
Contract Duration: 111 days
Daily Burn Rate: $678/day
Competition Type: FULL AND OPEN COMPETITION
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: POP 01/01/2025-03/31/2025
Place of Performance
Location: CASS LAKE, CASS County, MINNESOTA, 56633
Plain-Language Summary
Department of Health and Human Services obligated $75,229.91 to ROCHE DIAGNOSTICS CORPORATION for work described as: POP 01/01/2025-03/31/2025 Key points: 1. Spending period is Q1 2025, totaling $752,299.91. 2. Roche Diagnostics Corporation is the sole awardee. 3. The contract is for In-Vitro Diagnostic Substance Manufacturing. 4. Awarded under full and open competition. 5. Delivery order placed by the Indian Health Service.
Value Assessment
Rating: good
The award amount of $752,299.91 for a 3-month period appears reasonable for specialized diagnostic substances. Benchmarking against similar contracts for in-vitro diagnostics would provide a more precise assessment of value.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, suggesting a competitive bidding process. This method generally leads to better price discovery and value for the government.
Taxpayer Impact: Taxpayer funds are being used efficiently through a competitive procurement process for essential health supplies.
Public Impact
Ensures availability of critical diagnostic substances for IHS facilities. Supports patient care and disease management within Native American communities. Maintains supply chain for essential medical testing.
Waste & Efficiency Indicators
Waste Risk Score: 67 / 10
Positive Signals
- Full and open competition utilized.
- Clear period of performance.
- Specific product category identified.
Sector Analysis
Spending in the medical supplies sector, particularly for diagnostic substances, is crucial for healthcare delivery. Benchmarks for similar contracts would indicate if this award is within the typical price range for specialized manufacturing.
Small Business Impact
The data indicates that Roche Diagnostics Corporation, a large business, received the award. There is no specific indication of small business participation in this particular delivery order.
Oversight & Accountability
The award is a delivery order under a larger contract, implying prior oversight. Further review of the base contract and any task order limitations would be necessary for a comprehensive oversight assessment.
Related Government Programs
- In-Vitro Diagnostic Substance Manufacturing
- Department of Health and Human Services Contracting
- Indian Health Service Programs
Risk Flags
- Potential for price escalation in future orders.
- Dependence on a single large supplier.
- Limited visibility into the base contract terms.
- Need for ongoing market research to ensure continued best value.
Tags
in-vitro-diagnostic-substance-manufactur, department-of-health-and-human-services, mn, delivery-order, under-100k
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $75,229.91 to ROCHE DIAGNOSTICS CORPORATION. POP 01/01/2025-03/31/2025
Who is the contractor on this award?
The obligated recipient is ROCHE DIAGNOSTICS CORPORATION.
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (Indian Health Service).
What is the total obligated amount?
The obligated amount is $75,229.91.
What is the period of performance?
Start: 2024-12-10. End: 2025-03-31.
What is the historical pricing trend for similar in-vitro diagnostic substances from Roche Diagnostics or competitors?
Analyzing historical pricing data for comparable in-vitro diagnostic substances from Roche Diagnostics and its competitors is essential. This would involve examining past contract awards, price lists, and market analyses to identify any significant deviations or trends. Understanding this context helps determine if the current award reflects fair and reasonable pricing or if there's potential for cost savings through further negotiation or competition.
What is the risk of supply chain disruption for these specific diagnostic substances?
The risk of supply chain disruption for these specific diagnostic substances depends on factors like the number of manufacturers, raw material availability, geopolitical stability, and the supplier's inventory management. Given Roche Diagnostics' established presence, the immediate risk might be moderate. However, a thorough assessment would involve understanding the criticality of these substances, lead times, and the existence of alternative suppliers or contingency plans to mitigate potential shortages.
How effectively do these diagnostic substances contribute to the Indian Health Service's mission and patient outcomes?
These in-vitro diagnostic substances are fundamental to the Indian Health Service's mission by enabling accurate and timely disease detection, diagnosis, and monitoring for patients. Their effectiveness directly impacts patient outcomes by facilitating appropriate treatment decisions, managing chronic conditions, and preventing the spread of infectious diseases. Ensuring a consistent and reliable supply of high-quality diagnostic materials is therefore critical for achieving the IHS's public health goals.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing
Product/Service Code: MEDICAL SERVICES › LABORATORY TESTING SERVICES
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Parent Company: Roche Holding AG
Address: 9115 HAGUE RD, INDIANAPOLIS, IN, 46256
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $75,230
Exercised Options: $75,230
Current Obligation: $75,230
Actual Outlays: $75,230
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Cost or Pricing Data: NO
Parent Contract
Parent Award PIID: 75H70519D00022
IDV Type: IDC
Timeline
Start Date: 2024-12-10
Current End Date: 2025-03-31
Potential End Date: 2025-03-31 00:00:00
Last Modified: 2026-04-01
More Contracts from Roche Diagnostics Corporation
- THE Purpose of This Contract IS to Procure the Procurement of Over the Counter (OTC) Covid-19 Tests — $90.6M (Department of Health and Human Services)
- Cost PER Test — $13.5M (Department of Veterans Affairs)
- CPT — $5.5M (Department of Veterans Affairs)
- Chemistry-Immunochemistry CPR — $4.6M (Department of Veterans Affairs)
- FY22 CPT Chemistry Analyzer — $4.2M (Department of Health and Human Services)
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →